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Keywords:
duration of disease was 4.3 (1–14) years. Four patients had limited
cutaneous SSc and eight had diffuse cutaneous SSc.
All SSc patients underwent treatmentwith calcium channel blockers
(Nifedipine 30 mg/day). None of the patients were treated with immu-
nosuppressive agents. Scleroderma patients with coronary arteryCardiopulmonary exercise test
Systemic sclerosis
Pulmonary arterial hypertension
Interstitial lung disease
Endothelin receptor antagonistsPulmonary arterial hypertension (PAH) and interstitial lung disease
(ILD) are serious pulmonary complications in patients with Systemic
sclerosis (SSc) [1] and despite recent advances in the treatment, remain
the major causes of death. Bosentan, a dual endothelin-1 receptor
antagonist is an effective approach to therapy for PAH, improving
pulmonary hemodynamics and functional capacity, and it is also able
to reduce the number of new digital ulcers in patients with SSc [2].
By contrast, Endothelin-1 receptor antagonist administered in idiopath-
ic pulmonary fibrosis was not associatedwith clear benefits increasing risk
for disease progression and respiratory hospitalizations [3].
The aim of this study is to evaluate the effects of bosentan adminis-
tered as prevention for digital ulcers (DUs), in SSc patients affected by
ILD, at baseline and post therapy with cardiopulmonary exercise test
(CPET) and pulmonary function tests (PFT).
Twelve consecutive SSc patients [8 females and 4males;median age
45 years (35–60)] in bosentan therapy for DUs prevention were
enrolled in this study. Median duration of disease was 4.5 (1–15)
years. Four patients had limited cutaneous SSc and eight had diffuse
cutaneous SSc.ome, Department of Clinical
Viale dell'Università 37, 00185
te).
.Twelve consecutive SSc patients [9 females and 3males;median age
46 years (37–58)] were enrolled in this study as control group. Median
disease, congestive heart failure, left ventricular dysfunction, pulmo-
nary hypertension, valvular abnormalities and arrhythmias were not
included in the study. Patients with diabetes mellitus, renal failure, he-
patic or thyroid dysfunction and anemia were excluded. Patients were
not taking β-blockers, antiarrhythmic drugs, ACE inhibitors or
angiotensin receptor antagonists.
The subjects'written consentwas obtained according to theDeclara-
tion of Helsinki and the study was approved by the Ethics Committee of
the Sapienza University. All examined patients underwent clinical eval-
uation, electrocardiography, transthoracic echocardiogram, baseline
PFT and high resolution computed tomography (HRCT) of the chest. A
maximal symptom-limited CPET was performed on an electronically
braked cycloergometer (Ergoline-800, Mortara, Bologna, Italy) accord-
ing to the recommendations on the use of exercise testing in clinical
practice [4]. The SSc patients with DUs underwent to CPET before
bosentan therapy (T0) and 24 months after bosentan therapy (T1). A
SSc group matched for sex and age was enrolled as control group and
underwent to CPET at enrollment (T0) and after 24 months (T1).
All data were expressed asmedian and range. TheMann–Whitney U
test or the Kruskal–Wallis was used to test differences between two
individual study groups. P-values b0.05 were considered significant.
In the SSc patients group treatedwith bosentanwe did not observed
any significant (p N 0,05) modification of PFTs and CPET parameters
after 24 months of bosentan therapy (Table 1). The median value of
single-breath carbon monoxide (CO) diffusing capacity (DLCO) was
80,6% (66,6–101,4%) at baseline and 72,5% (63,1–90,2%) post bosentan
therapy. Also the relation between minute ventilation (VE) and carbon
dioxide output (VCO2) (VE/VCO2 slope) did not showed any significant
modification (p N 0,05) post bosentan therapy: 26,4 (18,2–51,2) vs 26,7
(21,4–44,4).
Also in SSc control group we did not observed any significant modi-
fication of PFTs and CPET parameters at T1 (Table 1). The median value
Table 1
Pulmonary function tests (PFT) and cardiopulmonary exercise test parameters in SSc patients in bosentan therapy and in SSc control group. All PFTs parameters are expressed as percent-
age of predicted.
SSc patients in bosentan therapy SSc control group
Pre Post Pre Post
FVC (%) 87,3 (62,6–108,8) 79,8 (56,8–102,9) 112,3 (61,5–120) 113,3 (71,9–121,5)
FEV1 (%) 87,3 (65,2–104,8) 85,8 (59–106,2) 108,9 (50,8–134) 107,5 (68,3–131,8)
DLCO (%) 80,6 (66,6–101,4) 72,5 (63,1–90,2) 78,9 (64,5–110) 78,8 (56–102,5)
VO2 max (L/min) 1335 (938–2048) 1293 (902–1867) 1328 (883–2521) 1259 (842–2095)
VE/VCO2 slope 26,4 (18,2–51,2) 26,7 (21,4–44,4) 29,5 (21,2–38,4) 25,8 (20,3–32,9)
PAPs (mm Hg) 26,5 (18–36) 27 (23−33) 30 (25–37) 29 (25–35)
FVC: Forced vital capacity, FEV1: forced expiratory volume in the 1st second,DLCO: single-breath carbonmonoxide (CO)diffusing capacity, VO2max:maximal oxygen consumption, PAPs:
pulmonary artery systolic pressure, VE/VCO2 slope: VE/VCO2 slope: relation between minute ventilation (VE) and carbon dioxide output (VCO2).
114 Correspondenceof DLCO was 78,9% (64,5–110,4%) at baseline and 78,8% (56–102,5%) at
T1. Also The VE/VCO2 slope did not show any significant modification a
T1: 29,5 (21,2–38,4) vs 25,8 (20,3–32,9) (Fig. 1).
In our study bosentan was safe in SSc patients with ILD not causing
imbalance ventilation perfusion as shownby parameters VE/VECO2 slope.
It is well known that in SSc patients endothelin 1 (ET-1) is able to
induce fibroblast chemotaxis and proliferation [5]. Although bosentan
has not shown antifibrotic effects, it is safe in the treatment of vascular
complications of SSc patients with ILD [6].
However, these vasodilators can worsen pulmonary hemodynamic,
producing an imbalance ventilation/perfusion due to inhibition of
hypoxic pulmonary vasoconstriction [7].
Rosato et al. have demonstrated that VE/VCO2 slope correlates with
disease severity and activity, thus suggesting a relationship betweenFig. 1. DLCO and VE/VECO2 slope in SSc patients in bosthis marker of ventilation-perfusion mismatch and SSc severity [8].
Moreover CPET was able to detect the early renal and cardiopulmonary
damage in asymptomatic SSc patients [9].
Thus, CPET is useful to assess ventilation/perfusion in ILD SSc
patients to evaluate any vasodilators side effects.
In conclusionwe can assume that bosentan, administered to preven-
tion digital ulcers in SSc patients affected by ILD without PAH, do not
cause a worsening CPET parameters and gas exchange.Conflict of interest
The authors report no relationships that could be construed as a con-
flict of interest.entan therapy (T0–T1) and control group (T0–T1).
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